The Lancet: March 25, 2008

Josef Smolen from the Medical University of Vienna, Austria, discusses in this week's podcast how the monoclonal antibody tocilizumab could be effective in treating rheumatoid arthritis. Tocilizumab blocks interleukin 6, a pro-inflammatory cytokine involved in the biological process behind rheumatoid arthritisContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.co...